Stock Events

Stock Events

Aldeyra Therapeutics 

$1.78
63
+$0.23+14.84% Tuesday 20:00

Statistics

Day High
1.74
Day Low
1.55
52W High
5.89
52W Low
1.24
Volume
1,109,042
Avg. Volume
-
Mkt Cap
107.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.28
-0.21
-0.13
-0.06
Expected EPS
-0.1125
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-111.7MNet Income

Analyst Ratings

2Average Price Target
The highest estimate is 2.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALDX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Vertex Pharmaceuticals is involved in creating treatments for inflammatory and autoimmune diseases, directly competing with Aldeyra's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals develops therapies for eye diseases, inflammation, and other areas, overlapping with Aldeyra's therapeutic targets.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie works on immunology and inflammatory diseases, competing in the same therapeutic areas as Aldeyra.
AMGEN
AMGN
Mkt Cap183.12B
Amgen focuses on treatments for inflammatory diseases and other serious illnesses, making it a competitor in Aldeyra's market.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences has a portfolio that includes treatments for inflammatory and respiratory diseases, areas Aldeyra is also targeting.
Biogen
BIIB
Mkt Cap28.61B
Biogen develops therapies for neurological and autoimmune diseases, competing with Aldeyra in the autoimmune space.
Adma Biologics
ADMA
Mkt Cap1.91B
ADMA Biologics is involved in the development of treatments for immune disorders, overlapping with Aldeyra's focus on immune-mediated diseases.
Incyte
INCY
Mkt Cap19.41B
Incyte Corporation focuses on oncology and inflammation, directly competing with Aldeyra in the development of treatments for inflammatory diseases.

About

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Show more...
CEO
Dr. Todd C. Brady M.D., Ph.D.
Employees
9
Country
United States
ISIN
US01438T1060

Listings

MU
DE
137.MU
STU
DE
137.STU
F
DE
137.F
XNAS
US
ALDX

0 Comments

Share your thoughts

FAQ

What is Aldeyra Therapeutics stock price today?▼
The current price of ALDX is $1.78 USD — it has increased by +14.84% in the past 24 hours. Watch Aldeyra Therapeutics stock price performance more closely on the chart.
What is Aldeyra Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aldeyra Therapeutics stocks are traded under the ticker ALDX.
Is Aldeyra Therapeutics stock price growing?▼
ALDX stock has risen by +14.84% compared to the previous week, the month change is a +12.66% rise, over the last year Aldeyra Therapeutics has showed a -19.09% decrease.
What is Aldeyra Therapeutics market cap?▼
Today Aldeyra Therapeutics has the market capitalization of 107.09M
When is the next Aldeyra Therapeutics earnings date?▼
Aldeyra Therapeutics is going to release the next earnings report on July 31, 2026.
What were Aldeyra Therapeutics earnings last quarter?▼
ALDX earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.12 USD resulting in a +50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aldeyra Therapeutics revenue for the last year?▼
Aldeyra Therapeutics revenue for the last year amounts to 0 USD.
What is Aldeyra Therapeutics net income for the last year?▼
ALDX net income for the last year is -111.7M USD.
How many employees does Aldeyra Therapeutics have?▼
As of May 27, 2026, the company has 9 employees.
In which sector is Aldeyra Therapeutics located?▼
Aldeyra Therapeutics operates in the Health & Wellness sector.
When did Aldeyra Therapeutics complete a stock split?▼
Aldeyra Therapeutics has not had any recent stock splits.
Where is Aldeyra Therapeutics headquartered?▼
Aldeyra Therapeutics is headquartered in Lexington, United States.